Publications by authors named "Nea Ojala"

Claim this Profile
S
Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes.
Tatiana V Kudling, Dmitrii Bychkov, James H A Clubb, Santeri A Pakola, Victor Arias, Nea Ojala

Cancer Gene Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models.
Santeri A Pakola, Nea Ojala, Tatiana V Kudling, James H A Clubb, Elise Jirovec

Cancer Immunol Immunother· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Boosting anti-tumor immunity with TILT-517 oncolytic adenovirus and checkpoint blockade in renal cell carcinoma.
Victor Arias, Tatiana V Kudling, James H A Clubb, Elise Jirovec, Santeri A Pakola, Nea Ojala

Mol Ther Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial.
Matthew Stephen Block, James Hugo Armstrong Clubb, Johanna Mäenpää, Santeri Pakola, Dafne Carolina Alves Quixabeira, Nea Ojala

Nat Commun· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis